Newsroom | 8110 results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and Development Officer to oversee an integrated R&D organization. Building on the launch of AMVUTTRA® in transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Alnylam is entering a new phase of growth, and a combined R&D organization will accelera...

COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, a digital health leader revolutionizing AI-driven cardiometabolic care, today announced its selection by Modern Healthcare as one of the 2025 Best Places to Work in Healthcare. This national award recognizes top employers in the healthcare industry. The highly competitive selection process, conducted in partnership with Workforce Research Group, involved an extensive employee survey. Welldoc was named to the list alongside a select group of health tech...

DUBLIN--(BUSINESS WIRE)--The "Peripheral Vascular Devices Industry, Global, 2024-2029" report has been added to ResearchAndMarkets.com's offering. This study analyzes peripheral vascular devices, such as metal stents, bioresorbable stents, drug-eluting stents, drug-coated balloons, percutaneous transluminal angioplasty (PTA) balloons, and catheters. The study provides insights into industry size, growth rates, growth opportunities, strategic imperatives, patient pathways, company market share,...

BORDEAUX, France--(BUSINESS WIRE)--DESKi, a healthtech company developing AI-powered diagnostic tools in collaboration with clinicians and researchers, today announced the close of a $6 million seed round to support the U.S. and global market launch of its FDA-approved cardiac imaging software, HeartFocus. The seed round was led by Racine², an impact-focused fund managed by Serena and Makesense, with participation from BNP Paribas Développement, Épopée Gestion, Good Only Ventures, Better Angle,...

BARCELONA, Spain--(BUSINESS WIRE)--ANACONDA Biomed, a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has announced that it has received CE Mark certification for its ANA5 Funnel Catheter. The CE marking confirms that the ANA5 device complies with the European Union's health, safety, and environmental protection standards, enabling its eventual commercial viability across the EU. The ANA5 Funnel Catheter is engineered to optimize...

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24, 2025...

SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, a leading global clinical research organization (CRO) and consultancy, proudly congratulates George Medicines on the U.S. Food and Drug Administration (FDA) approval of WIDAPLIK™ (telmisartan, amlodipine and indapamide), a novel single pill combination treatment for hypertension in adults, including as initial treatment, to lower blood pressure. The approval of WIDAPLIK™ marks a significant milestone for George Medicines and the patients who will...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced enrollment completion for the ongoing, global registrational Phase 3 PROSERA Study evaluating seralutinib in Functional Class II and III PAH patients. Gossamer Bio and t...

東京--(BUSINESS WIRE)--(美國商業資訊)-- HekaBio K.K.（總部：東京中央區；總裁兼執行長：Robert E. Claar；以下簡稱「HekaBio」）今日宣布與日本首屈一指的藥品批發商Alfresa Holdings Corporation（總部：東京千代田區；代表董事兼總裁：Ryuji Arakawa；以下簡稱「Alfresa Holdings」）簽署策略性合作夥伴協議。根據該協議，Alfresa Holdings還對HekaBio進行了資本投資。此次合作旨在加快創新醫療產品在日本的商業化。 背景與目的 近年來，日本已實施政策改革，以解決日益擴大的可及性差距問題——在海外獲准的創新療法進入日本市場的速度緩慢。 針對這些發展，HekaBio專注於將全球市場的尖端藥品、醫療器材和再生醫學產品引進日本及亞太市場。HekaBio利用專有的全球網路與合作模式，每年評估200多項腫瘤學、心臟病學和中樞神經系統領域的資產，並支援從授權到臨床和監管開發、製造和銷售的端對端商業化。 與Alfresa Group的這一合作將使HekaBio能夠推進和擴充其產品組合及影響力...

TOKYO--(BUSINESS WIRE)--HekaBio K.K. (Headquarters: Chuo-ku, Tokyo; President & CEO: Robert E. Claar; hereinafter “HekaBio”) today announced the signing of a strategic partnership agreement with Alfresa Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; Representative Director & President: Ryuji Arakawa; hereinafter “Alfresa Holdings”), the leading pharmaceutical wholesaler group in Japan. As part of this agreement, Alfresa Holdings has also made a capital investment in HekaBio. The...